Stocks · News reference

8-K filing — ONCOLYTICS BIOTECH INC (ONCY)

Sep 10, 2026, 12:17 PMSEC EDGAR

Filed: 2026-09-10 AccNo: 0001129928-26-000055 Size: 161 KB Item 8.01: Other Events

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 10, 2026, 12:16 PMBenzinga Newsdesk
Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in
ONCY
BenzingaAug 19, 2026, 12:37 PMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.
ONCY
BenzingaAug 18, 2026, 1:03 PMBenzinga Newsdesk
Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design
Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating
ONCY